Prostate cancer is a malignant tumor of the prostate gland, usually adenocarcinoma, and is one of the most common cancers in men.
PCF invests $6.3M in 31 Young Investigator Awards, supports Creativity Awards, and hosts Home Run Challenge 2026 to raise awareness. The foundation has contributed to 15 FDA-approved therapies over its 30-year history.
Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.
The FDA has cleared an IND for Amphista's novel BRD9 degrader AMX-883 for AML, approved Lantheus' new prostate cancer imaging agent Pylarify TruVu, and accepted Biofrontera's sNDA for Ameluz PDT in superficial basal cell carcinoma. These regulatory milestones span hematologic and solid tumor areas, addressing significant unmet medical needs.
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
Novartis expands US radioligand manufacturing with new Texas and North Carolina facilities to bolster domestic production of cancer treatments. Telix Pharmaceuticals reports positive Phase 3 prostate cancer trial data and maintains 2026 revenue guidance of US$950-970 million.
Key oncology developments include a $315 million partnership between Astellas and Vir for the prostate cancer T-cell engager VIR-5500, with updated phase 1 data showing an 82% PSA50 rate. The FDA accepted a filing for Ono Pharmaceuticals' tirabrutinib seeking accelerated approval in primary central nervous system lymphoma. Research findings also identified a new kidney cancer biomarker and showed promising results for the TRK inhibitor repotrectinib and the breast cancer triple therapy gedatolisib plus palbociclib and fulvestrant.
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
Telix Pharmaceuticals reported full-year 2025 revenue of US$803.8 million, up 56% year-over-year, driven by strong growth in its Precision Medicine segment and the successful U.S. launch of Gozellix. The company issued 2026 revenue guidance of US$950-970 million and advanced multiple regulatory filings and late-stage pipeline programs.
Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.
European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07610083 |
A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer |
NOT_YET_RECRUITING | |
| NCT07608419 |
Predictors of Nodal and Distant Metastatic Disease Detected by PSMA PET in Treatment-Naïve High-Risk Prostate Cancer: A Czech Multicentre Cohort Study |
ACTIVE_NOT_RECRUITING | |
| NCT07607431 |
Risk Factors, Incidence, and Progression of Lymphedema Among Men With Prostate Cancer. The AWARE Cohort |
ACTIVE_NOT_RECRUITING | |
| NCT07605936 |
Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study |
RECRUITING | |
| NCT07600554 |
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07597369 |
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer |
ACTIVE_NOT_RECRUITING | |
| NCT07594002 |
Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy |
NOT_YET_RECRUITING | NA |
| NCT07593079 |
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07591701 |
Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital |
NOT_YET_RECRUITING | NA |
| NCT07591467 |
Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer |
NOT_YET_RECRUITING | PHASE3 |
